CoChat

Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRASG12C

Open access
Kettle, Jason G., Bagal, Sharan K., Bickerton, Sue, Bodnarchuk, Michael S., Breed, Jason, Carbajo, Rodrigo J., Cassar, Doyle J., Chakraborty, Atanu, Cosulich, Sabina, Cumming, Iain, Davies, Michael, Eatherton, Andrew, Evans, Laura, Feron, Lyman, Fillery, Shaun, Gleave, Emma S., Goldberg, Frederick W., Harlfinger, Stephanie, Hanson, Lyndsey, Howard, Martin, Howells, Rachel, Jackson, Anne, Kemmitt, Paul, Kingston, Jennifer K., Lamont, Scott, Lewis, Hilary J., Li, Songlei, Liu, Libin, Ogg, Derek, Phillips, Christopher, Polanski, Radek, Robb, Graeme, Robinson, David, Ross, Sarah, Smith, James M., Tonge, Michael, Whiteley, Rebecca, Yang, Junsheng, Zhang, Longfei, Zhao, Xiliang · 2020 · Journal of Medicinal Chemistry
Cited by 82

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

Abstract Attempts to directly drug the important oncogene KRAS have met with limited success despite numerous efforts across industry and academia. The KRASG12C mutant represents an “Achilles heel” and has recently yielded to covalent targeting with small molecules that bind the mutant cysteine and create an allosteric pocket on GDP-bound RAS, locking it in an inactive state. A weak inhibitor at this site was optimized through conformational locking of a piperazine–quinazoline motif and linker modification. Subsequent introduction of a key methyl group to the piperazine resulted in enhancements in potency, permeability, clearance, and reactivity, leading to identification of a potent KRASG12C inhibitor with high selectivity and excellent cross-species pharmacokinetic parameters and in vivo efficacy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.9b01720

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Research works printed but not linked: 8

  1. Quevedo, 2018, Small Molecule Inhibitors of RAS-Effector Protein Interactions Derived Using an Intracellular Antibody Fragment, Nat. Commun., 9, 3169, 10.1038/s41467-018-05707-2 · DOI · Paper page
  2. Winter, 2015, Small Molecule Binding Sites on the Ras:SOS Complex Can Be Exploited for Inhibition of Ras Activation, J. Med. Chem., 58, 2265, 10.1021/jm501660t · DOI · Paper page
  3. Hodges, 2018, Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RAS, J. Med. Chem., 61, 8875, 10.1021/acs.jmedchem.8b01108 · DOI · Paper page
  4. Ross, 2015, Water Sites, Networks, and Free Energies with Grand Canonical Monte Carlo, J. Am. Chem. Soc., 137, 14930, 10.1021/jacs.5b07940 · DOI · Paper page
  5. Bodnarchuk, 2014, Strategies to Calculate Water Binding Free Energies in Protein-Ligand Complexes, J. Chem. Inf. Model., 54, 1623, 10.1021/ci400674k · DOI
  6. Shibata, 2015, The Role of Extrahepatic Metabolism in the Pharmacokinetics of the Targeted Covalent Inhibitors Afatinib, Ibrutinib, and Neratinib, Drug Metab. Dispos., 43, 375, 10.1124/dmd.114.061424 · DOI
  7. Collisson, 2011, Subtypes of Pancreatic Ductal Adenocarcinoma and their Differing Responses to Therapy, Nat. Med., 17, 500, 10.1038/nm.2344 · DOI · Paper page
  8. Singh, 2009, A Gene Expression Signature Associated with ″K-Ras Addiction″ Reveals Regulators of EMT and Tumor Cell Survival, Cancer Cell, 15, 489, 10.1016/j.ccr.2009.03.022 · DOI · Paper page

Cited by

See all 82

Metadata

Authors
Kettle, J. G., Bagal, S. K., Bickerton, S., Bodnarchuk, M. S., Breed, J., Carbajo, R. J., Cassar, D. J., Chakraborty, A., Cosulich, S., Cumming, I., Davies, M., Eatherton, A., Evans, L., Feron, L., Fillery, S., Gleave, E. S., Goldberg, F. W., Harlfinger, S., Hanson, L., Howard, M., Howells, R., Jackson, A., Kemmitt, P., Kingston, J. K., Lamont, S., Lewis, H. J., Li, S., Liu, L., Ogg, D., Phillips, C., Polanski, R., Robb, G., Robinson, D., Ross, S., Smith, J. M., Tonge, M., Whiteley, R., Yang, J., Zhang, L., & Zhao, X.
Venue
Journal of Medicinal Chemistry
Published
2020-02-05
Volume
63
Issue
9
Pages
4468-4483
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W3004429666
Cited by
82
References
26
FWCI
3.46
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRASG12C. https://app.cochat.ai/papers/10.1021/acs.jmedchem.9b01720
The paper
Kettle, J. G., Bagal, S. K., Bickerton, S., Bodnarchuk, M. S., Breed, J., Carbajo, R. J., Cassar, D. J., Chakraborty, A., Cosulich, S., Cumming, I., Davies, M., Eatherton, A., Evans, L., Feron, L., Fillery, S., Gleave, E. S., Goldberg, F. W., Harlfinger, S., Hanson, L., . . . Zhao, X. (2020). Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRASG12C. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.9b01720

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.